Cancer Stem Cell News Volume 9.44 | Nov 25 2020







2020-11-25 | CSC 9.44


Cancer Stem Cell News by STEMCELL Technologies
Vol. 9.44 – 25 November, 2020
TOP STORY

The
Lipogenic Regulator SREBF2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

The authors showed that single circulating tumor cells from melanoma patients coordinately upregulated lipogenesis and iron homeostasis pathways.
[Cancer Discovery]

Abstract

Scientific resources to support your cancer research. Learn More!
PUBLICATIONSRanked by the impact factor of the journal

S100
Calcium-Binding Protein A9 from Tumor-Associated Macrophage Enhances Cancer Stem Cell-Like Properties of Hepatocellular Carcinoma

S100A9 expression in tumor tissues was associated with poor survival of hepatocellular carcinoma patients. It could enhance the stem cell‐like properties of HepG2 and MHCC‐97H cells by activating nuclear factor‐kappa B signaling pathway through advanced glycosylation end product‐specific receptor in a Ca2+‐dependent manner.
[International Journal of Cancer]

Abstract

Cancer-Initiating
Cells in Human Pancreatic Cancer Organoids Are Maintained by Interactions with Endothelial Cells

Organoid-derived CD44() cancer cells were capable of organoid re-formation and could be re-programed as CD44-expressing cancer-initiating cells in the organoid culture system.
[Cancer Letters]

Abstract

MiR-22,
Regulated by MeCP2, Suppresses Gastric Cancer Cell Proliferation by Inducing a Deficiency in Endogenous S-Adenosylmethionine

Scientists revealed that the metabolic profiles in gastric cancer tissues were altered. S-adenosylmethionine, a universal methyl donor for histone and DNA methylation, which is specifically involved in the epigenetic maintenance of cancer cells, was found increased.
[Oncogenesis]

Full Article

Astaxanthin
Reduces Stemness Markers in BT20 and T47D Breast Cancer Stem Cells by Inhibiting Expression of Pontin and Mutant p53

Using Western blotting and qRT-PCR analyses, investigators revealed that in the T47D and BT20 breast cancer cell lines, astaxanthin inhibited expression of pontin and mutp53, as well as the Oct4 and Nanog CSC stemness genes.
[Marine Drugs]

Full Article

Evaluation of Chemotherapy and P2Et Extract Combination in Ex Vivo
Derived Tumor Mammospheres from Breast Cancer Patients

Researchers evaluated the presence of breast CSCs as well as markers related to drug resistance in tumors obtained from 78 patients who had received (or not) chemotherapy before surgery.
[Scientific Reports]

Full Article

Automated
Enumeration and Phenotypic Characterization of CTCs and tdEVs in Patients with Metastatic Castration Resistant Prostate Cancer

The authors investigated the prognostic value of automated circulating tumor cell (CTC) and tumor-derived extracellular vesicle enumeration and their dynamics, in patients with metastatic castration-resistant prostate cancer in the context of the initiation of treatment with androgen receptor signaling inhibitors.
[Prostate Cancer and Prostatic Diseases]

Full Article

Long
Non-Coding RNA FOXD3-AS1 Silencing Exerts Tumor Suppressive Effects in Nasopharyngeal Carcinoma by Downregulating FOXD3 Expression via microRNA-185-3p Upregulation

The relationship among lncRNA FOXD3-AS1, miR-185-3p, and FOXD3 was identified with bioinformatics prediction, dual-luciferase reporter gene assays, RNA-binding protein immunoprecipitation, and RNA pull-down assays.
[Cancer Gene Therapy]

Abstract

A Lipidomic Signature Complements Stemness Features Acquisition in Liver Cancer Cells

Researchers found definite lipidomic and transcriptomic changes in the hepatocellular carcinoma lines upon knockdown of macroH2A1 or FAK, in line with the acquisition or loss of stemness features.
[International Journal of Molecular Sciences]

Full Article

Cancer
Stem Cell Markers in Relation to Patient Survival Outcomes: Lessons for Integrative Diagnostics and Next-Generation Anticancer Drug Development

Investigators report original findings on expression and prognostic significance of CSC markers in several cancers. They examined and compared the transcriptional expression of CSC markers in tumor tissues versus the adjacent normal tissues using publicly available databases, The Cancer Genome Atlas and Gene Expression Profiling Interactive Analysis.
[Omics-A Journal of integrative Biology]

Abstract


How have LSCs changed our understanding of myeloid malignancies? Webinar by Dr. Christopher Park, NYU
REVIEWS

Epigenetic Regulation of Cancer Stem Cell Formation and Maintenance

Accumulating evidence suggests that tumors arise from cells with stem‐like properties, the generation of CSCs is therefore likely to be an initiatory event in carcinogenesis
[International Journal of Cancer]

Abstract

Mitochondrial
Rewiring through Mitophagy and Mitochondrial Biogenesis in Cancer Stem Cells: A Potential Target for Anti-CSC Cancer Therapy

Scientists discuss their coordinated regulation in the elimination of CSCs, with respect to stemness and differentiation of the CSC phenotype, and the different aspects of tumorigenesis such as cancer initiation, progression, resistance, and tumor relapse.
[Cancer Letters]

Abstract
INDUSTRY AND POLICY NEWS

BeiGene
Announces the Approval of XGEVA® (Denosumab) in China for the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors and in Patients with Multiple Myeloma

BeiGene, Ltd. announced that the China National Medical Products Administration has approved XGEVA® for the prevention of skeletal-related events in patients with bone metastases from solid tumors and in patients with multiple myeloma.
[BeiGene, Ltd.]

Press Release

GT
Medical Technologies Announces $16 Million Financing to Expand Availability of Targeted Therapy for Patients with Recurrent Brain Tumors

GT Medical Technologies, Inc. announced it has raised $16 million in a Series B financing led by MVM Partners with participation from existing investors MedTech Venture Partners and BlueStone Venture Partners. Funds from the round will support the expanded commercialization of GammaTile® Therapy, an FDA-cleared, Surgically Targeted Radiation Therapy for patients with brain tumors.
[GT Medical Technologies, Inc. (Business Wire, Inc.)]

Press Release

FEATURED EVENT

The American Association for Cancer Research (AACR) Annual Meeting 2021

April 9 – April 14, 2021
Virtual


> See All Events

JOB OPPORTUNITIES

Senior
Investigator – Replication Stress and Chromatin Alterations

NIH National Cancer Institute – Bethesda, Maryland, United States

Postdoctoral
Research Assistant – Glioblastoma

Queen Mary University of London – London, England, United Kingdom

Dean and Faculty Positions – Brain Cancer Biology

Peking University Shenzhen Graduate School – Shenzhen, China

Postdoctoral Fellow – Melanoma

NYU Langone Medical Center – New York, New York, United States

Senior Group Leader – Rare Cancers

IRCCS Candiolo Cancer Institute – Candiolo, Italy

> See All Jobs

Submit an article, publication, job or event
Brought to you by
stemcell-logo-for newsletter-2
Science News Cancer Stem Cell News
Archives Contact Us
Cancer Stem Cell News Twitter


0
Share